

# Subsets of exhausted CD8<sup>+</sup> T cells differentially mediate checkpoint blockade

Nature Immunology

20, 326-336

DOI: [10.1038/s41590-019-0312-6](https://doi.org/10.1038/s41590-019-0312-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. <i>Cell Reports</i> , 2019, 28, 2140-2155.e6.	2.9	64
2	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. <i>Cell</i> , 2019, 178, 933-948.e14.	13.5	301
3	Effect and biomarker of Nivolumab for non-“small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109199.	2.5	22
4	Clonal replacement of tumor-specific T cells following PD-1 blockade. <i>Nature Medicine</i> , 2019, 25, 1251-1259.	15.2	974
5	CXCR3-CXCL9: It’s All in the Tumor. <i>Immunity</i> , 2019, 50, 1347-1349.	6.6	69
6	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. <i>Cancer Immunology Research</i> , 2019, 7, 1958-1969.	1.6	87
7	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. <i>BMC Biotechnology</i> , 2019, 19, 67.	1.7	15
8	New Clones on the Block. <i>Immunity</i> , 2019, 51, 606-608.	6.6	4
9	Common gamma chain cytokines and CD8 T cells in cancer. <i>Seminars in Immunology</i> , 2019, 42, 101307.	2.7	25
10	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. <i>Seminars in Immunology</i> , 2019, 42, 101306.	2.7	17
11	Intratumoral CD8 <sup>+</sup> T cells with stem cell-like properties: Implications for cancer immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	42
12	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 3546-3555.	0.8	78
13	Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy. <i>Journal of Controlled Release</i> , 2019, 315, 65-75.	4.8	26
14	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2019, 59, 236-250.	4.3	200
15	Striking a Balance” Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation. <i>Frontiers in Immunology</i> , 2019, 10, 1595.	2.2	23
16	<i>Dendrobium officinale</i> polysaccharides alleviate colon tumorigenesis via restoring intestinal barrier function and enhancing anti-tumor immune response. <i>Pharmacological Research</i> , 2019, 148, 104417.	3.1	87
17	Defining “T cell exhaustion”™. <i>Nature Reviews Immunology</i> , 2019, 19, 665-674.	10.6	879
18	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection. <i>Nature Immunology</i> , 2019, 20, 890-901.	7.0	361
20	Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 14113-14118.	3.3	157
21	Tissue-Resident Memory T Cells in Cancer Immunosurveillance. <i>Trends in Immunology</i> , 2019, 40, 735-747.	2.9	123
22	Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. <i>Cell Reports</i> , 2019, 27, 3315-3330.e7.	2.9	106
23	Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity. <i>Journal of Immunology</i> , 2019, 203, 725-735.	0.4	21
24	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
25	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624.	1.7	32
26	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
27	States of exhaustion. <i>Nature Reviews Cancer</i> , 2019, 19, 185-185.	12.8	1
28	Ineffective treatment of PML with pembrolizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e627.	3.1	39
29	Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1. <i>Trends in Immunology</i> , 2019, 40, 1149-1162.	2.9	70
30	Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy. <i>Cancers</i> , 2019, 11, 1832.	1.7	38
31	SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond. <i>Vaccines</i> , 2019, 7, 184.	2.1	8
32	PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. , 2019, 7, 331.		213
33	PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. <i>Nature Immunology</i> , 2019, 20, 1335-1347.	7.0	142
34	Developing neoantigen-targeted T cell-based treatments for solid tumors. <i>Nature Medicine</i> , 2019, 25, 1488-1499.	15.2	173
35	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
36	Antitumour T cells stand the test of time. <i>Nature</i> , 2019, 576, 392-393.	13.7	2

#	ARTICLE	IF	CITATIONS
37	Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. <i>Nature</i> , 2019, 576, 471-476.	13.7	251
38	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019, 576, 465-470.	13.7	510
39	Precursor exhausted T cells: key to successful immunotherapy?. <i>Nature Reviews Immunology</i> , 2020, 20, 128-136.	10.6	253
40	TIM3 comes of age as an inhibitory receptor. <i>Nature Reviews Immunology</i> , 2020, 20, 173-185.	10.6	535
41	Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. <i>International Immunopharmacology</i> , 2020, 78, 106012.	1.7	40
42	Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 27-35.	4.8	168
43	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 114-122.	4.3	45
44	Prevention of CAR-T-cell dysfunction. <i>Nature Biomedical Engineering</i> , 2020, 4, 16-17.	11.6	2
45	Generating stem-like memory T cells with antioxidants for adoptive cell transfer immunotherapy of cancer. <i>Methods in Enzymology</i> , 2020, 631, 137-158.	0.4	8
46	Memory T cell, exhaustion, and tumor immunity. <i>Immunological Medicine</i> , 2020, 43, 1-9.	1.4	118
47	Prostate cancer research: The next generation; report from the 2019 Coffey & Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020, 80, 113-132.	1.2	25
48	Stem, Effector, and Hybrid States of Memory CD8+ T Cells. <i>Trends in Immunology</i> , 2020, 41, 17-28.	2.9	65
49	Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications. <i>Trends in Immunology</i> , 2020, 41, 29-45.	2.9	46
50	Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 589641.	2.2	21
51	Landscape of Exhausted Virus-Specific CD8+ T Cells in Chronic LCMV Infection. <i>Cell Reports</i> , 2020, 32, 108078.	2.9	45
52	Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. <i>Journal of Autoimmunity</i> , 2020, 115, 102546.	3.0	13
53	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	142
54	Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. <i>Cell</i> , 2020, 183, 1117-1133.e19.	13.5	66

#	ARTICLE	IF	CITATIONS
55	Cellular and Molecular Mechanisms of CD8+ T Cell Differentiation, Dysfunction and Exhaustion. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7357.	1.8	43
56	Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. <i>Nature Immunology</i> , 2020, 21, 1552-1562.	7.0	167
57	p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy. , 2020, 8, e001365.		12
58	The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer. <i>Trends in Immunology</i> , 2020, 41, 982-993.	2.9	19
59	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. <i>Nature Immunology</i> , 2020, 21, 1540-1551.	7.0	252
60	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. <i>Nature Medicine</i> , 2020, 26, 1878-1887.	15.2	321
61	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
62	Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. <i>Nature Immunology</i> , 2020, 21, 1022-1033.	7.0	227
63	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	7.0	85
64	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
65	Obesity, COVID-19 and immunotherapy: the complex relationship!. <i>Immunotherapy</i> , 2020, 12, 1105-1109.	1.0	18
66	Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e133.	1.7	17
67	Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy. <i>Small</i> , 2020, 16, e2004905.	5.2	16
68	The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion. <i>Cells</i> , 2020, 9, 2470.	1.8	58
69	CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. <i>Cell Reports Medicine</i> , 2020, 1, 100127.	3.3	70
70	Induction of Progenitor Exhausted Tissue-Resident Memory CD8+ T Cells Upon Salmonella Typhi Porins Adjuvant Immunization Correlates With Melanoma Control and Anti-PD-1 Immunotherapy Cooperation. <i>Frontiers in Immunology</i> , 2020, 11, 583382.	2.2	9
71	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	2.2	39
72	Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31319-31330.	3.3	29

#	ARTICLE	IF	CITATIONS
73	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
74	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 586907.	2.2	40
75	Memory CD8+ T cell responses to cancer. <i>Seminars in Immunology</i> , 2020, 49, 101435.	2.7	89
76	Determinants of Tissue-Specific Metabolic Adaptation of T Cells. <i>Cell Metabolism</i> , 2020, 32, 908-919.	7.2	27
77	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
78	Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. <i>Scientific Reports</i> , 2020, 10, 20846.	1.6	14
79	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
80	CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1995-2009.	4.8	26
81	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
82	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.	15.2	87
83	T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	17
84	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. <i>Cancer Research</i> , 2020, 80, 3906-3919.	0.4	36
85	NRP1 cripples immunological memory. <i>Nature Immunology</i> , 2020, 21, 972-973.	7.0	4
86	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020, 28, 2379-2393.	3.7	49
87	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. <i>Cells</i> , 2020, 9, 1727.	1.8	8
88	Cell and tissue engineering in lymph nodes for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 42-62.	6.6	43
89	â€œTo Anticipateâ€ Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1941.	1.7	4
90	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. <i>Nature Communications</i> , 2020, 11, 5415.	5.8	85

#	ARTICLE	IF	CITATIONS
91	Resident Memory T Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 39-68.	0.8	3
92	Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. <i>Immunity</i> , 2020, 53, 985-1000.e11.	6.6	107
93	Persistent STAT5 activation reprograms the epigenetic landscape in CD4 <sup>+</sup> T cells to drive polyfunctionality and antitumor immunity. <i>Science Immunology</i> , 2020, 5, .	5.6	40
94	Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion. <i>Frontiers in Immunology</i> , 2020, 11, 592569.	2.2	25
95	Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. <i>PLoS ONE</i> , 2020, 15, e0238380.	1.1	16
96	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , 2020, 2, 1001-1012.	5.1	167
97	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. <i>Nature Communications</i> , 2020, 11, 4835.	5.8	290
98	Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1168.	1.7	17
99	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	8
100	Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 <sup>+</sup> CD8 <sup>+</sup> T cell abundance. <i>OncImmunology</i> , 2020, 9, 1810489.	2.1	7
101	Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection. <i>Nature Communications</i> , 2020, 11, 4454.	5.8	32
102	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23684-23694.	3.3	32
103	The Transcription Factor TCF1 in T Cell Differentiation and Aging. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6497.	1.8	49
104	Intratumoral TIGIT <sup>+</sup> CD8 <sup>+</sup> T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
105	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. <i>ESMO Open</i> , 2020, 5, e000791.	2.0	25
106	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. <i>Cancers</i> , 2020, 12, 2326.	1.7	6
107	Early precursor T cells establish and propagate T cell exhaustion in chronic infection. <i>Nature Immunology</i> , 2020, 21, 1256-1266.	7.0	160
108	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 6410.	5.8	66

#	ARTICLE	IF	CITATIONS
109	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020, 11, 600886.	2.2	43
110	Quality of CD8 <sup>+</sup> T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. <i>Science Advances</i> , 2020, 6, .	4.7	24
111	Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. <i>Cell</i> , 2020, 183, 1848-1866.e26.	13.5	347
112	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	6.0	273
113	T cell factor 1: A master regulator of the T cell response in disease. <i>Science Immunology</i> , 2020, 5, .	5.6	85
114	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 158-173.	0.4	85
115	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. <i>Frontiers in Immunology</i> , 2020, 11, 587014.	2.2	56
116	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	1.8	59
117	Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 849.	2.2	79
118	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
119	FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 586.	1.3	42
120	Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1989-1999.	2.0	75
121	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1140-1157.	7.7	97
122	IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. <i>Nature</i> , 2020, 583, 609-614.	13.7	195
123	A single-cell atlas of the peripheral immune response in patients with severe COVID-19. <i>Nature Medicine</i> , 2020, 26, 1070-1076.	15.2	1,300
124	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 340.	2.2	27
125	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
126	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	2.2	20



#	ARTICLE	IF	CITATIONS
127	Immunotherapeutic Potential of TGF- $\beta$ 2 Inhibition and Oncolytic Viruses. <i>Trends in Immunology</i> , 2020, 41, 406-420.	2.9	55
128	Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. <i>Genome Medicine</i> , 2020, 12, 22.	3.6	98
129	T Cell Dysfunction and Exhaustion in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 17.	1.8	226
130	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. <i>Frontiers in Immunology</i> , 2020, 11, 1350.	2.2	13
131	cGAS-STING-mediated DNA sensing maintains CD8 <sup>+</sup> T cell stemness and promotes antitumor T cell therapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	121
132	Rapid in vitro generation of bona fide exhausted CD8 <sup>+</sup> T cells is accompanied by Tcf7 promoter methylation. <i>PLoS Pathogens</i> , 2020, 16, e1008555.	2.1	36
133	The Contribution of Epigenetics to Cancer Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 676-691.	2.9	133
134	PD-1 <sup>+</sup> stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4292-4299.	3.3	85
135	Use of Mass Cytometry to Profile Human T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2019, 10, 3039.	2.2	37
136	Peripheral T cell expansion predicts tumour infiltration and clinical response. <i>Nature</i> , 2020, 579, 274-278.	13.7	439
137	Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway. <i>Nature Communications</i> , 2020, 11, 821.	5.8	25
138	Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2020, 26, 2640-2653.	3.2	204
139	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
140	VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance. <i>Science</i> , 2020, 367, .	6.0	156
141	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. <i>International Journal of Cancer</i> , 2020, 147, 1509-1518.	2.3	44
142	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
143	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	7.7	444
144	Forget "EM" not virtual memory T cells. <i>Nature Immunology</i> , 2020, 21, 499-500.	7.0	8

#	ARTICLE	IF	CITATIONS
145	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. <i>Gastroenterology</i> , 2020, 159, 609-623.	0.6	100
146	4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation. <i>Frontiers in Immunology</i> , 2020, 11, 577.	2.2	21
147	Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq. <i>Oncolimmunology</i> , 2020, 9, 1737369.	2.1	42
148	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. <i>Cancer Immunology Research</i> , 2020, 8, 869-882.	1.6	16
149	Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. <i>BMC Immunology</i> , 2020, 21, 22.	0.9	14
150	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
151	CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 912-925.	1.6	53
152	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
153	Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1262-1277.	4.8	49
154	PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. <i>Cellular and Molecular Immunology</i> , 2021, 18, 385-397.	4.8	37
155	Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines. <i>Clinical and Translational Science</i> , 2021, 14, 120-131.	1.5	3
156	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. <i>International Immunology</i> , 2021, 33, 39-48.	1.8	4
157	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. <i>Blood</i> , 2021, 137, 2463-2480.	0.6	35
158	Opposing Roles of Type I Interferons in Cancer Immunity. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 167-198.	9.6	88
159	Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 685-697.	0.4	31
160	Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 889-902.	3.2	41
161	Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 184-199.	1.6	74
162	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49

#	ARTICLE	IF	CITATIONS
163	Origin and fine-tuning of effector CD8 T cell subpopulations in chronic infection. <i>Current Opinion in Virology</i> , 2021, 46, 27-35.	2.6	4
164	Role, function and regulation of the thymocyte selection-associated high mobility group box protein in CD8+ T cell exhaustion. <i>Immunology Letters</i> , 2021, 229, 1-7.	1.1	9
165	Immunometabolism in the Tumor Microenvironment. <i>Annual Review of Cancer Biology</i> , 2021, 5, 137-159.	2.3	28
166	SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2021, 206, 193-205.	0.4	40
167	Direct and Indirect Regulators of Epithelialâ€“Mesenchymal Transitionâ€“Mediated Immunosuppression in Breast Carcinomas. <i>Cancer Discovery</i> , 2021, 11, 1286-1305.	7.7	76
168	Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. <i>Pathobiology</i> , 2021, 88, 218-227.	1.9	2
169	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 136-146.	1.6	12
170	Human CXCR5 <sup>+</sup> PD <sup>+</sup> CD8 T cells in healthy individuals and patients with hematologic malignancies. <i>European Journal of Immunology</i> , 2021, 51, 703-713.	1.6	11
171	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
172	Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 41-52.	7.0	110
173	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , 2021, 33, 27-37.	1.8	8
174	Reinvigorating exhausted CD8 <sup>+</sup> cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
175	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 215-229.	12.5	486
176	Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2179-2195.	2.0	22
177	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1555-1567.	1.4	17
179	Postinfectious Epigenetic Immune Modifications â€” A Double-Edged Sword. <i>New England Journal of Medicine</i> , 2021, 384, 261-270.	13.9	30
180	Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 613815.	2.2	26
182	Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection. <i>Nature Immunology</i> , 2021, 22, 229-239.	7.0	95

#	ARTICLE	IF	CITATIONS
183	Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. <i>Nature Immunology</i> , 2021, 22, 205-215.	7.0	358
184	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 622509.	2.2	148
185	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 544339.	1.3	18
186	Intratumoral heterogeneity in cancer progression and response to immunotherapy. <i>Nature Medicine</i> , 2021, 27, 212-224.	15.2	376
187	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 370-380.	7.0	75
188	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 832.	5.8	248
189	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. <i>JCI Insight</i> , 2021, 6, .	2.3	43
190	Editorial: Memory T Cells in Chronic Infections and Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 656010.	2.2	0
191	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 74.	3.5	19
192	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 561083.	2.2	12
193	A Regenerative Perspective on Successful and Failed T-Cell Immunity. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037937.	2.3	2
194	Biomechanics of T Cell Dysfunctions in Chronic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 600829.	2.2	11
195	TIGIT/CD226 Axis Regulates Anti-Tumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 200.	1.7	58
196	Not All Tumor-Infiltrating CD8+ T Cells Are Created Equal. <i>Cancer Cell</i> , 2021, 39, 145-147.	7.7	5
197	Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation. <i>Frontiers in Immunology</i> , 2020, 11, 592328.	2.2	3
198	Role of the Orphan Nuclear Receptor NR4A Family in T-Cell Biology. <i>Frontiers in Endocrinology</i> , 2020, 11, 624122.	1.5	53
199	Therapeutic depletion of CCR8 <sup>+</sup> tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. , 2021, 9, e001749.		91
200	Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. <i>JCI Insight</i> , 2021, 6, .	2.3	37

#	ARTICLE	IF	CITATIONS
201	Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions. <i>Cancer Immunology Research</i> , 2021, 9, 637-650.	1.6	6
202	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 331, 321-334.	4.8	35
203	Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 643291.	2.2	52
204	Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	74
205	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. <i>Blood Advances</i> , 2021, 5, 1816-1829.	2.5	22
206	Memory T-Cell Heterogeneity and Terminology. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037929.	2.3	26
207	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	15.2	90
208	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 655697.	2.2	126
209	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
210	Resident memory T cells form during persistent antigen exposure leading to allograft rejection. <i>Science Immunology</i> , 2021, 6, .	5.6	43
211	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 2782-2791.	3.2	21
212	Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR <sup>T</sup> -cell responses against ALL. <i>Blood</i> , 2021, 138, 122-135.	0.6	28
213	CD8+ T Cell Responses during HCV Infection and HCC. <i>Journal of Clinical Medicine</i> , 2021, 10, 991.	1.0	22
214	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 1797-1804.	2.5	26
216	Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2021, 9, 651-664.	1.6	43
217	Identification of hub genes associated with neutrophils infiltration in colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3371-3380.	1.6	15
218	Harnessing the IL-21-BATF Pathway in the CD8+ T Cell Anti-Tumor Response. <i>Cancers</i> , 2021, 13, 1263.	1.7	17
219	Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1895-1909.	1.0	5

#	ARTICLE	IF	CITATIONS
220	The architectural design of CD8+ T cell responses in acute and chronic infection: Parallel structures with divergent fates. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	41
221	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
222	COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3525-3540.	2.0	15
223	Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. <i>Drug Discovery Today</i> , 2021, 26, 951-967.	3.2	25
224	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
225	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. <i>Cancer Discovery</i> , 2021, 11, 2186-2199.	7.7	85
226	Malignant Pleural Effusionsâ€”A Window Into Local Anti-Tumor T Cell Immunity?. <i>Frontiers in Oncology</i> , 2021, 11, 672747.	1.3	9
227	Metabolic Control of Memory T-Cell Generation and Stemness. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037770.	2.3	6
228	Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3461-3475.	2.0	19
229	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
230	The Complex Integration of T-cell Metabolism and Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1636-1643.	7.7	64
231	Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	66
232	T cell metabolism in homeostasis and cancer immunity. <i>Current Opinion in Biotechnology</i> , 2021, 68, 240-250.	3.3	20
233	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
234	Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. , 2021, 9, e002347.		35
235	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	6.0	297
236	Role of TCFâ€”1 in differentiation, exhaustion, and memory of CD8 <sup>+</sup> T cells: A review. <i>FASEB Journal</i> , 2021, 35, e21549.	0.2	24
237	Sequence of Î±PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. <i>Science Immunology</i> , 2021, 6, .	5.6	81

#	ARTICLE	IF	CITATIONS
238	Resistance mechanisms to checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 47-55.	2.4	19
239	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021, 21, 769-784.	10.6	83
240	The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 653625.	1.3	12
242	Modular, efficient and constant-memory single-cell RNA-seq preprocessing. <i>Nature Biotechnology</i> , 2021, 39, 813-818.	9.4	252
243	Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. , 2021, 9, e002231.		69
244	CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674467.	1.8	22
245	Interpretation of T cell states from single-cell transcriptomics data using reference atlases. <i>Nature Communications</i> , 2021, 12, 2965.	5.8	210
246	Chemokines and the immune response to cancer. <i>Immunity</i> , 2021, 54, 859-874.	6.6	254
247	TCF-1 maintains CD8+ T cell stemness in tumor microenvironment. <i>Journal of Leukocyte Biology</i> , 2021, 110, 585-590.	1.5	14
248	Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	19
250	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
251	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
252	PD-1 blockade prevents the progression of oral carcinogenesis. <i>Carcinogenesis</i> , 2021, 42, 891-902.	1.3	14
253	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	1.5	25
254	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5
255	Targeting monoamine oxidase A for T cell-based cancer immunotherapy. <i>Science Immunology</i> , 2021, 6, .	5.6	35
256	Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. <i>Nature Immunology</i> , 2021, 22, 746-756.	7.0	160
257	High endothelial venules (HEVs) in immunity, inflammation and cancer. <i>Angiogenesis</i> , 2021, 24, 719-753.	3.7	64

#	ARTICLE	IF	CITATIONS
258	Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 660944.	2.2	37
259	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. <i>Journal of Immunology and Regenerative Medicine</i> , 2021, 12, 100042.	0.2	0
260	How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. <i>Trends in Immunology</i> , 2021, 42, 401-417.	2.9	18
261	Immune Regulation in Time and Space: The Role of Local- and Long-Range Genomic Interactions in Regulating Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 662565.	2.2	13
262	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. <i>Nature Communications</i> , 2021, 12, 3080.	5.8	34
263	In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. , 2021, 9, e002432.		21
264	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	53
265	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021, 11, 2582-2601.	7.7	62
266	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 346-359.	4.2	70
267	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
268	Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. <i>Nature Communications</i> , 2021, 12, 2782.	5.8	20
269	Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 2924.	1.7	18
270	Transcriptional Control of Cell Fate Determination in Antigen-Experienced CD8 T Cells. <i>Cold Spring Harbor Perspectives in Biology</i> , 2022, 14, a037945.	2.3	4
271	Exploiting the obesity-associated immune microenvironment for cancer therapeutics. , 2022, 229, 107923.		10
272	TCF1 in T cell immunity: a broadened frontier. <i>Nature Reviews Immunology</i> , 2022, 22, 147-157.	10.6	100
273	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. <i>Nature Immunology</i> , 2021, 22, 1052-1063.	7.0	61
274	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
275	TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. <i>Nature</i> , 2021, 595, 101-106.	13.7	169



#	ARTICLE	IF	CITATIONS
276	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	0.9	21
277	Not-so-opposite ends of the spectrum: CD8 <sup>+</sup> T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113
278	Identification of a T-bethi Quiescent Exhausted CD8 T Cell Subpopulation That Can Differentiate into TIM3 <sup>+</sup> CX3CR1 <sup>+</sup> Effectors and Memory-like Cells. <i>Journal of Immunology</i> , 2021, 206, 2924-2936.	0.4	17
279	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 592-606.	1.8	11
280	Multi-Omics Approaches in Immunological Research. <i>Frontiers in Immunology</i> , 2021, 12, 668045.	2.2	22
281	Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with a high frequency of melanoma-infiltrating CXCR3 <sup>+</sup> resident memory CD8 <sup>+</sup> T cells and multiple chemokine pathways. <i>British Journal of Dermatology</i> , 2021, 185, 663-666.	1.4	1
283	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 483-490.	3.6	48
284	Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	139
285	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. <i>PLoS ONE</i> , 2021, 16, e0251731.	1.1	9
286	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 690499.	2.2	59
287	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	3.2	20
288	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
289	CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?. <i>Clinical Cancer Research</i> , 2021, 27, 5742-5752.	3.2	98
290	Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. <i>European Journal of Immunology</i> , 2021, 51, 1911-1920.	1.6	31
292	A unified atlas of CD8 T cell dysfunctional states in cancer and infection. <i>Molecular Cell</i> , 2021, 81, 2477-2493.e10.	4.5	57
293	Type 17 immunity promotes the exhaustion of CD8 <sup>+</sup> T cells in cancer. , 2021, 9, e002603.		20
294	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	1.8	13
295	T-cell Exhaustion in Organ Transplantation. <i>Transplantation</i> , 2022, 106, 489-499.	0.5	14

#	ARTICLE	IF	CITATIONS
296	CD8+ T Cell Exhaustion in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 715234.	2.2	163
297	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	30
298	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , 2021, 27, 4781-4793.	3.2	14
299	PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 <sup>+</sup> T cell exhaustion during metastasis. <i>Cancer Science</i> , 2021, 112, 3437-3454.	1.7	33
300	Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. <i>Nature Immunology</i> , 2021, 22, 1020-1029.	7.0	124
301	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. <i>Immunity</i> , 2021, 54, 1561-1577.e7.	6.6	260
303	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
304	BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. <i>Nature Immunology</i> , 2021, 22, 983-995.	7.0	147
305	Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. <i>Nature Immunology</i> , 2021, 22, 1008-1019.	7.0	116
306	COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7481.	1.8	37
307	The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 670391.	2.2	48
308	Subsetting the subsets: Heterogeneity and developmental relationships of T cells in human tumors. <i>Science Immunology</i> , 2021, 6, .	5.6	3
309	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
311	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
312	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021, 27, 1250-1261.	15.2	159
314	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. <i>Cell Reports</i> , 2021, 36, 109422.	2.9	89
315	BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. <i>Nature Immunology</i> , 2021, 22, 996-1007.	7.0	78
316	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	13.7	239

#	ARTICLE	IF	CITATIONS
317	The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. <i>Cancer Cell</i> , 2021, 39, 945-957.e10.	7.7	124
318	Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. <i>Cancer Cell</i> , 2021, 39, 928-944.e6.	7.7	158
319	CD8+ T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1794-1803.	2.0	5
320	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 1141-1157.	1.6	33
321	Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4139.	1.7	10
322	Transforming growth factor- $\beta$ -regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. <i>Immunity</i> , 2021, 54, 1698-1714.e5.	6.6	82
323	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9401.	1.8	16
324	Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. <i>Seminars in Immunology</i> , 2021, 52, 101485.	2.7	24
325	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 4245.	1.7	13
326	Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. <i>Immunity</i> , 2021, 54, 1825-1840.e7.	6.6	64
327	Transcriptome Signature of $\text{V}\alpha$ 2 T Cells Treated With Phosphoantigens and Notch Inhibitor Reveals Interplay Between TCR and Notch Signaling Pathways. <i>Frontiers in Immunology</i> , 2021, 12, 660361.	2.2	6
328	Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 726492.	2.2	17
329	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. <i>Nature Communications</i> , 2021, 12, 5138.	5.8	28
330	The Ratio of Exhausted to Resident Infiltrating Lymphocytes Is Prognostic for Colorectal Cancer Patient Outcome. <i>Cancer Immunology Research</i> , 2021, 9, 1125-1140.	1.6	18
331	Fc $\gamma$ R engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. <i>Nature Communications</i> , 2021, 12, 4791.	5.8	55
332	High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 736670.	2.2	26
334	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. <i>Cells</i> , 2021, 10, 2234.	1.8	10
335	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	45

#	ARTICLE	IF	CITATIONS
336	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , 2021, 39, 1342-1360.e14.	7.7	119
337	Combining an Alarmin HMG1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 1214-1228.	1.6	12
340	Counting on You: How MHC Tetramers Revolutionized the Study of T Cell Memory and CD8+ T Cell Exhaustion. <i>Journal of Immunology</i> , 2021, 207, 1225-1227.	0.4	1
341	The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. <i>BMC Cancer</i> , 2021, 21, 969.	1.1	13
342	CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. <i>Cell</i> , 2021, 184, 4512-4530.e22.	13.5	180
343	Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. <i>Future Oncology</i> , 2021, 17, 3477-3484.	1.1	23
344	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	7.7	165
345	Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure. <i>Cancers</i> , 2021, 13, 4529.	1.7	10
346	Advances in Treatment of Progressive Multifocal Leukoencephalopathy. <i>Annals of Neurology</i> , 2021, 90, 865-873.	2.8	18
347	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
348	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. <i>Nature Cancer</i> , 2021, 2, 1071-1085.	5.7	57
349	Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. <i>Cells</i> , 2021, 10, 2563.	1.8	12
350	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. <i>Cancers</i> , 2021, 13, 4660.	1.7	2
351	Tumor reactivity of CD8 <sup>+</sup> T cells favors acquisition of dysfunctional states in human melanoma. <i>Immunology and Cell Biology</i> , 2021, 99, 914-916.	1.0	0
353	Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. <i>Cell</i> , 2021, 184, 4996-5014.e26.	13.5	84
355	Global Pattern of CD8+ T-Cell Infiltration and Exhaustion in Colorectal Cancer Predicts Cancer Immunotherapy Response. <i>Frontiers in Pharmacology</i> , 2021, 12, 715721.	1.6	9
357	Active surveillance characterizes human intratumoral T cell exhaustion. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
359	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10

#	ARTICLE	IF	CITATIONS
360	The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. <i>Science</i> , 2021, 373, 1327-1335.	6.0	83
361	The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723609.	2.2	17
362	The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e726-e730.	0.2	1
363	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. <i>Immunity</i> , 2021, 54, 2338-2353.e6.	6.6	111
364	A reservoir of stem-like CD8 <sup>+</sup> T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. <i>Science Immunology</i> , 2021, 6, eabg7836.	5.6	123
365	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. <i>Cell</i> , 2021, 9, e003464.		60
366	Highly proliferative and functional PD-1+ and TIM-3+ T cells are transiently increased in multiple myeloma following autologous hematopoietic stem cell transplantation. <i>International Immunopharmacology</i> , 2021, 100, 108093.	1.7	2
367	Diverse Roles of Akt in T cells. <i>Immunometabolism</i> , 2021, 3, .	0.7	16
369	Chromatin accessibility profiling methods. <i>Nature Reviews Methods Primers</i> , 2021, 1, .	11.8	95
370	The Cxxc1 subunit of the Trithorax complex directs epigenetic licensing of CD4+ T cell differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	10
371	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. <i>JCI Insight</i> , 2021, 6, .	2.3	64
372	Destiny of CD8+ T cells exhaustion in cancer, and rescue of it: a narrative review. <i>Annals of Blood</i> , 0, .	0.4	0
373	Contribution of resident and circulating precursors to tumor-infiltrating CD8 <sup>+</sup> T cell populations in lung cancer. <i>Science Immunology</i> , 2021, 6, .	5.6	82
374	New cytometry tools for immune monitoring during cancer immunotherapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 10-18.	0.7	11
375	B7-H3 $\alpha$ -4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 <sup>+</sup> tumor-infiltrating lymphocytes. <i>Science Advances</i> , 2021, 7, .	4.7	31
376	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8 <sup>+</sup> T cells. <i>Science Immunology</i> , 2021, 6, .	5.6	185
377	Heterogenous Populations of Tissue-Resident CD8+ T Cells Are Generated in Response to Infection and Malignancy. <i>Immunity</i> , 2020, 52, 808-824.e7.	6.6	149
378	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. <i>Immunity</i> , 2020, 52, 825-841.e8.	6.6	497

#	ARTICLE	IF	CITATIONS
379	Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 104876.	3.1	17
380	CD8+ T cell states in human cancer: insights from single-cell analysis. <i>Nature Reviews Cancer</i> , 2020, 20, 218-232.	12.8	766
381	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	5.7	74
382	Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer. <i>Clinical Science</i> , 2020, 134, 711-726.	1.8	20
404	CX3CR1hiCD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. <i>JCI Insight</i> , 2020, 5, .	2.3	48
405	DNA hypermethylation during tuberculosis dampens host immune responsiveness. <i>Journal of Clinical Investigation</i> , 2020, 130, 3113-3123.	3.9	47
406	Memory like NK cells display stem cell like properties after Zika virus infection. <i>PLoS Pathogens</i> , 2020, 16, e1009132.	2.1	9
407	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
408	Exhausted T cells and epigenetic status. <i>Cancer Biology and Medicine</i> , 2020, 17, 923-936.	1.4	32
409	T <sub>FR</sub> Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
410	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
411	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7139.	1.8	33
412	Re-defining T-Cell Exhaustion: Subset, Function, and Regulation. <i>Immune Network</i> , 2020, 20, e2.	1.6	33
413	Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy. <i>Immune Network</i> , 2020, 20, e3.	1.6	45
414	SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. <i>ELife</i> , 2020, 9, .	2.8	19
415	The effects of age and systemic metabolism on anti-tumor T cell responses. <i>ELife</i> , 2020, 9, .	2.8	34
416	Spatiotemporal Co-Dependency between Macrophages and Exhausted CD8 <sup>+</sup> T Cells in Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
417	Chronic LCMV Infection Is Fortified with Versatile Tactics to Suppress Host T Cell Immunity and Establish Viral Persistence. <i>Viruses</i> , 2021, 13, 1951.	1.5	3

#	ARTICLE	IF	CITATIONS
418	Programmed death (PD)-1/PD-L1 ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. <i>Cancer Science</i> , 2021, 112, 4853-4866.	1.7	6
419	Targeting Cbx3/HP1 <sup>3</sup> Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence. <i>Frontiers in Immunology</i> , 2021, 12, 738958.	2.2	2
420	Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. <i>Cell Reports</i> , 2021, 37, 109844.	2.9	120
421	Improving CAR T-Cell Persistence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10828.	1.8	44
423	The prognostic value of TCF1+CD8+T in primary small cell carcinoma of the esophagus. <i>Cancer Science</i> , 2021, 112, 4968-4976.	1.7	6
424	Metabolic regulation of the cancer-immunity cycle. <i>Trends in Immunology</i> , 2021, 42, 975-993.	2.9	28
425	Targeted Anti-CTumor Immunotherapy Using Tumor Infiltrating Cells. <i>Advanced Science</i> , 2021, 8, e2101672.	5.6	36
426	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
427	Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. <i>Annual Review of Medicine</i> , 2022, 73, 251-265.	5.0	30
428	Dynamic regulatory networks of T cell trajectory dissect transcriptional control of T cell state transition. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1115-1129.	2.3	11
430	Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice. , 2021, 9, e002809.		11
431	Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy. <i>Cytotherapy</i> , 2021, , .	0.3	2
432	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	3.7	29
433	Effects of nitric oxide donor N,N <sup>TM</sup> -di-sec-butyl-N,N <sup>TM</sup> -dinitroso-1,4-phenylenediamine on the expression of interferon-gamma in tumor infiltrating lymphocytes. <i>Medical Gas Research</i> , 2019, 9, 171.	1.2	3
446	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
447	Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. <i>Science Immunology</i> , 2021, 6, eabi8800.	5.6	58
450	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020, 20, e48.	1.6	10
451	å...ç-«ãfã,Şãfã,ãfã,ãfã»å³å%ã®äl/2œç”æ©ÿåªã•ãfã,ã,ªãfžãf¼ã,ããf¼. <i>Skin Cancer</i> , 2021, 36, 133-138.1		0

#	ARTICLE	IF	CITATIONS
452	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
453	Myeloid antigen-presenting cell niches sustain antitumor T <sup>H</sup> 1 cells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	7.7	64
454	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	5.6	22
459	Novel genetic variants of and of the endosome-related pathway predict cutaneous melanoma-specific survival. American Journal of Cancer Research, 2020, 10, 3382-3394.	1.4	0
460	Ageing-associated immune system changes in multiple myeloma: The dark side of the moon.. Cancer Treatment and Research Communications, 2021, 29, 100494.	0.7	6
461	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers, 2021, 13, 5856.	1.7	39
462	Mapping the evolution of T <sup>H</sup> 1 cell states during response and resistance to adoptive cellular therapy. Cell Reports, 2021, 37, 109992.	2.9	37
463	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. Cancers, 2021, 13, 5911.	1.7	1
464	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 759217.	2.2	18
465	CXCL10 chemokine regulates heterogeneity of the CD8 <sup>+</sup> T <sup>H</sup> 1 cell response and viral set point during chronic infection. Immunity, 2022, 55, 82-97.e8.	6.6	33
466	mTOR-dependent translation drives tumor infiltrating CD8 <sup>+</sup> effector and CD4 <sup>+</sup> Treg cells expansion. ELife, 2021, 10, .	2.8	5
467	Dynamic CD4 <sup>+</sup> T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nature Immunology, 2021, 22, 1524-1537.	7.0	26
468	Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells. Frontiers in Immunology, 2021, 12, 706150.	2.2	2
469	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications, 2021, 12, 6938.	5.8	93
470	LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nature Communications, 2021, 12, 6831.	5.8	46
471	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 777073.	2.2	5
472	Selective IL-1 activity on CD8 <sup>+</sup> T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication. , 2021, 9, e003293.		9
473	Mutant IDH Inhibits IFN $\gamma$ -TET2 Signaling to Promote Immuno-evasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery, 2022, 12, 812-835.	7.7	55



#	ARTICLE	IF	CITATIONS
474	Expression of PD-1 and TIM-3 inhibitory checkpoint molecules by T-lymphocytes in early post-transplant period in multiple myeloma patients. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 499-511.	0.1	0
475	Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. <i>Blood</i> , 2022, 139, 2156-2172.	0.6	33
476	T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma. <i>Frontiers in Veterinary Science</i> , 2021, 8, 772932.	0.9	4
478	Optimal Target Saturation of Ligand-Blocking Anti-GITR Antibody IBI37G5 Dictates Fc $\gamma$ 3R-Independent GITR Agonism and Antitumor Activity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
479	Tertiary lymphoid structures in cancer. <i>Science</i> , 2022, 375, eabf9419.	6.0	303
480	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	0
481	Therapeutic potential of CAR T cell in malignancies: A scoping review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112512.	2.5	56
482	512â€¦Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors. , 2020, , .		0
483	Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. <i>Onc Immunology</i> , 2021, 10, 1997385.	2.1	23
485	Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. <i>Nature Communications</i> , 2022, 13, 440.	5.8	100
486	Application of Machine Learning for Cytometry Data. <i>Frontiers in Immunology</i> , 2021, 12, 787574.	2.2	30
487	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. <i>Nature Communications</i> , 2022, 13, 256.	5.8	8
488	Editorial: Immune Cell Lineage Reprogramming in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 838464.	2.2	2
489	Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting. <i>Nature Biomedical Engineering</i> , 2022, 6, 108-117.	11.6	31
490	G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. , 2022, 10, e003543.		10
491	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
492	Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 799453.	1.3	5
493	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 303-313.	1.6	1

#	ARTICLE	IF	CITATIONS
494	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. <i>Scientific Reports</i> , 2022, 12, 1342.	1.6	7
495	Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 967-978.	2.0	1
496	Differential expression of inhibitory receptor NKG2A distinguishes disease-specific exhausted CD8 + T cells. <i>MedComm</i> , 2022, 3, e111.	3.1	2
497	TCR-T Immunotherapy: The Challenges and Solutions. <i>Frontiers in Oncology</i> , 2021, 11, 794183.	1.3	36
498	Lighting up the tumor fire with low-dose irradiation. <i>Trends in Immunology</i> , 2022, 43, 173-179.	2.9	26
499	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
500	PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. <i>Frontiers in Immunology</i> , 2022, 13, 770132.	2.2	7
501	A Signature of N6-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 809872.	2.2	7
503	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	2.7	15
504	Antigen cross-presentation in young tumor-bearing hosts promotes CD8 <sup>+</sup> T cell terminal differentiation. <i>Science Immunology</i> , 2022, 7, eabf6136.	5.6	5
506	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2022, 40, 318-334.e9.	7.7	97
507	ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma. <i>Medical Oncology</i> , 2022, 39, 51.	1.2	4
508	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	17
509	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425.	0.4	9
511	Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer. <i>Oncolimmunology</i> , 2022, 11, 2034257.	2.1	11
512	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 <sup>int</sup> TCF-1 <sup>+</sup> CD8 <sup>+</sup> T cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
513	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	5.7	150
515	Epigenetics and CD8 <sup>+</sup> T cell memory*. <i>Immunological Reviews</i> , 2022, 305, 77-89.	2.8	22

#	ARTICLE	IF	CITATIONS
516	Pan-cancer single-cell landscape of tumor-infiltrating T cells. <i>Science</i> , 2021, 374, abe6474.	6.0	460
517	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 793808.	1.3	2
518	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
519	Chronic Type I Interferons Signaling Promotes Lipid Peroxidation-Driven Terminal CD8 T Cell Exhaustion and Curtails Anti-PD-1 Treatment Efficacy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
520	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1581-1588.	2.9	16
521	Clinical Significance of BTLA and HVEM Expression on Circulating CD4 <sup>+</sup> T and CD8 <sup>+</sup> T Cells in Chronic Hepatitis B Virus Infection. <i>Viral Immunology</i> , 2022, 35, 291-302.	0.6	5
522	A comprehensive profile of TCF1+ progenitor and TCF1 <sup>hi</sup> terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. <i>International Journal of Oral Science</i> , 2022, 14, 8.	3.6	18
523	Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. <i>Ageing and Cancer</i> , 2022, 3, 68-83.	0.5	5
524	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	6.0	156
525	Knowns and Unknowns about CAR-T Cell Dysfunction. <i>Cancers</i> , 2022, 14, 1078.	1.7	23
526	Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. , 2022, 10, e003525.		5
527	Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2022, 77, 332-343.	1.8	19
528	What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. <i>OncImmunology</i> , 2022, 11, 2038403.	2.1	7
530	Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2549-2563.	2.0	24
531	Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Frontiers in Immunology</i> , 2022, 13, 809414.	2.2	6
532	Metabolic dynamics instruct CD8 <sup>+</sup> T cell differentiation and functions. <i>European Journal of Immunology</i> , 2022, 52, 541-549.	1.6	15
533	Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing. <i>Genome Biology</i> , 2022, 23, 87.	3.8	24
534	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2022, 34, 234-242.	1.1	16

#	ARTICLE	IF	CITATIONS
535	Stem-cell-like T <sup>A</sup> cells have a specific entry gate to the tumor. <i>Cancer Cell</i> , 2022, 40, 243-245.	7.7	4
536	Tumor-Infiltrating T Cells – A Portrait. <i>New England Journal of Medicine</i> , 2022, 386, 992-994.	13.9	10
537	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 612-625.	1.6	12
538	Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer. , 2022, 10, e003667.		26
539	Tfh-cell-derived interleukin 21 sustains effector CD8+ T <sup>A</sup> cell responses during chronic viral infection. <i>Immunity</i> , 2022, 55, 475-493.e5.	6.6	48
540	Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy. <i>Biomedicines</i> , 2022, 10, 805.	1.4	6
541	Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. , 2022, 10, e003959.		10
544	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T <sup>A</sup> cell responses. <i>Immunity</i> , 2022, 55, 512-526.e9.	6.6	118
545	A novel nano–immunotherapeutic remodels the immune landscape of malignant pleural effusion: Insights into its mechanism of action through single–cell RNA–sequencing. <i>Clinical and Translational Medicine</i> , 2022, 12, e774.	1.7	2
546	Tumor endothelial cell–induced CD8 <sup>+</sup> T <sup>A</sup> cell exhaustion via GPNMB in hepatocellular carcinoma. <i>Cancer Science</i> , 2022, 113, 1625-1638.	1.7	18
547	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	25
549	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
550	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T <sup>A</sup> cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29
551	Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. <i>Nature Biomedical Engineering</i> , 2022, 6, 310-324.	11.6	16
552	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	1.8	8
553	An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. <i>Nature Cancer</i> , 2022, 3, 337-354.	5.7	41
554	Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T <sup>A</sup> cells in distinct cellular niches. <i>Immunity</i> , 2022, 55, 656-670.e8.	6.6	41
555	Dahuang Fuzi Baijiang decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer. <i>Cancer Science</i> , 2022, 113, 1739-1751.	1.7	9

#	ARTICLE	IF	CITATIONS
556	TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. , 2022, 10, e004711.		69
557	Spatial analysis of cellular arrangement using quantitative, single-cell imaging of protein multiplexing. , 2022, , .		0
558	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. Journal of Clinical Investigation, 2022, 132, .	3.9	15
559	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	2.3	13
560	Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188720.	3.3	26
561	Multimodal predictors for precision immunotherapy. Immuno-Oncology Technology, 2022, 14, 100071.	0.2	4
563	Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection. Virology Journal, 2021, 18, 242.	1.4	2
564	Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases. Journal of NeuroVirology, 2022, 28, 145-150.	1.0	6
565	Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade. Cancer Immunology Research, 2022, 10, 146-153.	1.6	87
566	Role of the tumor immune microenvironment in tumor immunotherapy (Review). Oncology Letters, 2021, 23, 53.	0.8	17
567	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
568	Combinatorial immunotherapy induces tumor-infiltrating CD8<sup>+</sup>T cells with distinct functional, migratory, and stem-like properties. , 2021, 9, e003614.		11
569	CRISPR Screens to Identify Regulators of Tumor Immunity. Annual Review of Cancer Biology, 2022, 6, 103-122.	2.3	5
571	Clinical and prognostic implications of an immune-related risk model based on <i>TP53</i> status in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2022, 26, 436-448.	1.6	3
572	Life support for transitory exhausted CTLs. Trends in Immunology, 2021, 42, 1057-1059.	2.9	1
573	Androgen conspires with the CD8 <sup>+</sup> T cell exhaustion program and contributes to sex bias in cancer. Science Immunology, 2022, 7, .	5.6	74
574	Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells. Frontiers in Immunology, 2022, 13, 866937.	2.2	5
575	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. Npj Precision Oncology, 2022, 6, 26.	2.3	13

#	ARTICLE	IF	CITATIONS
576	Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. <i>Cell</i> , 2022, 185, 1694-1708.e19.	13.5	100
578	Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. <i>Cancer Cell</i> , 2022, 40, 393-409.e9.	7.7	59
580	Elevated CD38 expression characterizes impaired CD8+ T cell immune response in metastatic pleural effusions. <i>Immunology Letters</i> , 2022, 245, 61-68.	1.1	2
594	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. <i>Cancer Cell</i> , 2022, 40, 479-493.e6.	7.7	64
595	The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. <i>Cell Metabolism</i> , 2022, 34, 731-746.e9.	7.2	63
596	A variety of "exhausted" T cells in the tumor microenvironment. <i>International Immunology</i> , 2022, 34, 563-570.	1.8	13
597	BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. <i>Cancer Immunology Research</i> , 2022, 10, 597-611.	1.6	16
598	Dissecting the heterogeneity of exhausted T cells at the molecular level. <i>International Immunology</i> , 2022, 34, 547-553.	1.8	2
599	A Unique Epigenomic Landscape Defines and CD8 <sup>+</sup> Tissue-Resident Memory T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
600	T-Cell Aging-Associated Phenotypes in Autoimmune Disease. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	14
601	TCF-1: a maverick in T cell development and function. <i>Nature Immunology</i> , 2022, 23, 671-678.	7.0	22
602	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	9.5	122
603	Landscape of helper and regulatory antitumor CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
604	Spatial determinants of CD8+ T cell differentiation in cancer. <i>Trends in Cancer</i> , 2022, 8, 642-654.	3.8	8
606	Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes. <i>Cancer Immunology Research</i> , 2022, 10, 800-810.	1.6	9
607	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. <i>Cancer Cell</i> , 2022, 40, 524-544.e5.	7.7	23
608	Macrophage-mediated tumor-targeted delivery of engineered <i>Salmonella typhimurium</i> VNP20009 in anti-PD1 therapy against melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3952-3971.	5.7	11
609	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1197-1206.	1.4	13

#	ARTICLE	IF	CITATIONS
610	Cancer evolution: special focus on the immune aspect of cancer. <i>Seminars in Cancer Biology</i> , 2022, , .	4.3	4
611	A novel four-gene signature predicts immunotherapy response of patients with different cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24494.	0.9	2
612	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
613	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 781-794.	1.8	10
615	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
616	Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. <i>Cancer Cell</i> , 2022, 40, 624-638.e9.	7.7	113
617	Rgs16 promotes antitumor CD8 <sup>+</sup> T cell exhaustion. <i>Science Immunology</i> , 2022, 7, .	5.6	25
618	Turning cold tumors hot: from molecular mechanisms to clinical applications. <i>Trends in Immunology</i> , 2022, 43, 523-545.	2.9	176
619	Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3. <i>Nature Immunology</i> , 2022, 23, 868-877.	7.0	32
620	Epigenetic regulation of T cell exhaustion. <i>Nature Immunology</i> , 2022, 23, 848-860.	7.0	82
621	“Stem-like” precursors are the fount to sustain persistent CD8+ T cell responses. <i>Nature Immunology</i> , 2022, 23, 836-847.	7.0	50
622	An integrated biomarker of PD-L1 expression and intraepithelial CD8 <sup>+</sup> T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases. <i>Thoracic Cancer</i> , 0, , .	0.8	3
623	Flow cytometry analysis of endothelial cells and subsets of exhausted CD8+ T cells in murine tumor models. <i>STAR Protocols</i> , 2022, 3, 101444.	0.5	1
624	Gasdermin D Restricts Anti-Tumor Immunity During PD-L1 Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
625	Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. <i>Immunity</i> , 2022, 55, 1268-1283.e9.	6.6	56
626	Exhaustion of CD39-expressing CD8+ T cells in Crohn’s disease is linked to clinical outcome. <i>Gastroenterology</i> , 2022, , .	0.6	7
627	Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity. <i>Cell Reports Medicine</i> , 2022, 3, 100660.	3.3	2
628	TCF1 and Tox define different subsets of CD4 T cells in patients with SÅzary syndrome. <i>Leukemia and Lymphoma</i> , 2022, 63, 2715-2718.	0.6	0

#	ARTICLE	IF	CITATIONS
629	Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
630	Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
631	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
632	Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. <i>Cancer Cell</i> , 2022, 40, 768-786.e7.	7.7	104
633	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
634	Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?. <i>Cells</i> , 2022, 11, 1854.	1.8	7
635	Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
636	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 932-946.	1.6	52
637	Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
638	Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer. <i>Nature Cell Biology</i> , 2022, 24, 1165-1176.	4.6	9
640	CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. <i>Nature Communications</i> , 2022, 13, .	5.8	11
641	The cellular and molecular basis of CD69 function in anti-tumor immunity. <i>International Immunology</i> , 2022, 34, 555-561.	1.8	11
642	Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 962-977.	1.6	12
643	A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. <i>Acta Biomaterialia</i> , 2022, 149, 334-346.	4.1	42
644	Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. <i>Anticancer Research</i> , 2022, 42, 3373-3380.	0.5	4
646	Application of ATAC-seq in tumor-specific T cell exhaustion. <i>Cancer Gene Therapy</i> , 2023, 30, 1-10.	2.2	4
647	The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
648	Self-antigens, benign autoimmunity and type 1 diabetes: a beta-cell and T-cell perspective. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 370-378.	1.2	5



#	ARTICLE	IF	CITATIONS
649	Downregulation of TCF1 in HIV Infection Impairs T-cell Proliferative Capacity by Disrupting Mitochondrial Function. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
650	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
651	The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
652	Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. <i>Nature Communications</i> , 2022, 13, .	5.8	70
655	Stem cell like memory T cells: A new paradigm in cancer immunotherapy. <i>Clinical Immunology</i> , 2022, 241, 109078.	1.4	12
656	The paradox of radiation and T cells in tumors. <i>Neoplasia</i> , 2022, 31, 100808.	2.3	9
657	Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma. <i>Cell Discovery</i> , 2022, 8, .	3.1	32
658	Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. <i>Journal of Autoimmunity</i> , 2022, 132, 102861.	3.0	23
659	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
661	SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8 <sup>+</sup> T cell cytotoxic function. <i>Science Advances</i> , 2022, 8, .	4.7	4
663	CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. <i>International Immunology</i> , 2022, 34, 571-577.	1.8	7
664	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
665	Uncovering CD4+ T-cell exhaustion in B-ALL. <i>Blood</i> , 2022, 140, 294-296.	0.6	0
666	Stem-like T cells and niches: Implications in human health and disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
668	Adenoviral-based vaccine promotes neoantigen-specific CD8 <sup>+</sup> T cell stemness and tumor rejection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	22
669	Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
670	CD39 <sup>+</sup> tissue-resident memory CD8 <sup>+</sup> T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	23
671	A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. <i>Cancers</i> , 2022, 14, 3796.	1.7	3

#	ARTICLE	IF	CITATIONS
672	TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
673	TGF- $\beta$ 2 promotes stem-like T cells via enforcing their lymphoid tissue retention. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	15
674	Stem-like memory T cells are generated during hollow fiber perfusion-based expansion and enriched after cryopreservation in an automated modular cell therapy manufacturing process. <i>Cytotherapy</i> , 2022, , .	0.3	2
675	Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. <i>Cell Reports</i> , 2022, 40, 111256.	2.9	25
676	Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. <i>Science Immunology</i> , 2022, 7, .	5.6	35
677	Characterization of gene expression profiles in the mouse brain after 35 days of spaceflight mission. <i>Npj Microgravity</i> , 2022, 8, .	1.9	4
678	Temporally restricted activation of IFN $\gamma$ signaling underlies response to immune checkpoint therapy in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	12
679	Epigenetic engineering for optimal CAR $\gamma$ cell therapy. <i>Cancer Science</i> , 0, , .	1.7	4
680	MYB orchestrates T cell exhaustion and response to checkpoint inhibition. <i>Nature</i> , 2022, 609, 354-360.	13.7	67
681	The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer. <i>Future Oncology</i> , 2022, 18, 3229-3244.	1.1	2
682	TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 174, 10-20.	1.3	9
683	Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10193-10200.	0.3	1
684	Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function. <i>EBioMedicine</i> , 2022, 84, 104254.	2.7	4
685	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. <i>Seminars in Cancer Biology</i> , 2022, 86, 14-27.	4.3	21
686	CD137 (4-1BB) Signaling Drives a TcR-Independent Exhaustion Program in CD8 T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
687	CXCL13 Modulates Immunoactive Tumor Microenvironment and Improves Prognosis in Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
688	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
690	Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 315-332.	2.0	9

#	ARTICLE	IF	CITATIONS
691	Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
692	PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. <i>Nature</i> , 2022, 610, 161-172.	13.7	81
693	Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. <i>JCI Insight</i> , 2022, 7, .	2.3	1
694	An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	9
695	Novel targets for immunotherapy associated with exhausted CD8+T cells in cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, .	1.2	1
696	Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. <i>Cancer Research</i> , 2022, 82, 4386-4399.	0.4	5
697	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
698	Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy. , 2022, 10, e001544.		5
699	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. <i>Nature Reviews Cancer</i> , 2022, 22, 640-656.	12.8	38
700	Metabolic plasticity and regulation of T cell exhaustion. <i>Immunology</i> , 2022, 167, 482-494.	2.0	14
701	ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
702	Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance. <i>Cancer Science</i> , 2022, 113, 3698-3709.	1.7	6
703	Immune dysfunction signatures predict outcomes and define checkpoint blockade“unresponsive microenvironments in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	23
704	Elicitation of stem-like CD8 <sup>+</sup> T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control. , 2022, 10, e005079.		2
705	Introduction: Redefining T-cell Exhaustion Special Issue. <i>International Immunology</i> , 2022, 34, 545-546.	1.8	0
707	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
708	The new progress in cancer immunotherapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 553-567.	1.9	6
709	Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
710	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
711	Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV. <i>Current HIV/AIDS Reports</i> , 2022, 19, 580-591.	1.1	2
712	Lipids for CD8+ TILs: Beneficial or harmful?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
713	Metabolic and epigenetic orchestration of (CAR) T cell fate and function. <i>Cancer Letters</i> , 2022, 550, 215948.	3.2	5
714	PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer. <i>Liver Cancer</i> , 2023, 12, 129-144.	4.2	2
715	Impact of cryopreservation on CAR T production and clinical response. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
716	The Transcription Factor Zfp335 Promotes Differentiation and Persistence of Memory CD8+ T Cells by Regulating TCF-1. <i>Journal of Immunology</i> , 2022, 209, 886-895.	0.4	3
717	Novel Lymphocytic Choriomeningitis Virus Strain Sustains Abundant Exhausted Progenitor CD8 T Cells without Systemic Viremia. <i>Journal of Immunology</i> , 2022, 209, 1691-1702.	0.4	2
718	TGF- $\beta$ 2-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	9
719	SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. <i>Nature Immunology</i> , 2022, 23, 1588-1599.	7.0	8
720	The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. <i>Cell</i> , 2022, 185, 4049-4066.e25.	13.5	89
722	Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. <i>Nature Communications</i> , 2022, 13, .	5.8	11
723	Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. <i>Nature Communications</i> , 2022, 13, .	5.8	28
724	Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1297-1309.	2.1	4
725	Cancer immunotherapy strategies that target the cGAS-STING pathway. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
726	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13241.	1.8	9
727	CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
728	Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1015-1027.	2.0	7

#	ARTICLE	IF	CITATIONS
729	VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. <i>Cancer Immunology Research</i> , 2023, 11, 38-55.	1.6	8
730	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
731	Cationic Polyethyleneimine (PEI)â€“Gold Nanocomposites Modulate Macrophage Activation and Reprogram Mouse Breast Triple-Negative MET-1 Tumor Immunological Microenvironment. <i>Pharmaceutics</i> , 2022, 14, 2234.	2.0	2
732	Cellular milieu in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
733	Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
735	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacistsâ€™ Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	1.0	2
736	Spatial maps of TÂcell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. <i>Immunity</i> , 2022, 55, 1940-1952.e5.	6.6	31
737	<b>The primordial differentiation of tumor specific memory CD8&amp;lt;sup&gt;+&lt;/sup&gt; T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes</b> . <i>Chinese Science Bulletin</i> , 2022, , .	0.4	0
738	A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	5
739	Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. <i>Cell Reports</i> , 2022, 41, 111553.	2.9	9
740	Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	27
741	Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses. , 2022, 10, e005398.		1
742	Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. <i>Translational Oncology</i> , 2023, 27, 101559.	1.7	1
743	Myeloid checkpoints for cancer immunotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 460-482.	0.7	7
744	The transcription factor IRF2 drives interferon-mediated CD8+ TÂcell exhaustion to restrict anti-tumor immunity. <i>Immunity</i> , 2022, 55, 2369-2385.e10.	6.6	29
745	Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against Cancer. <i>Immunological Investigations</i> , 2022, 51, 2128-2132.	1.0	2
746	Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. <i>International Immunology</i> , 2023, 35, 67-77.	1.8	0
747	CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15

#	ARTICLE	IF	CITATIONS
748	Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 <sup>+</sup> T cells. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1139-1151.	2.0	1
749	mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	18
750	Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8 <sup>+</sup> T cell exhaustion and curtails anti-PD-1 efficacy. <i>Cell Reports</i> , 2022, 41, 111647.	2.9	12
751	Advancing beyond the twists and turns of T cell exhaustion in cancer. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	13
752	Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. , 2022, 19, 1347-1360.		9
753	COVID-19 vaccination in patients with cancer: Opportunities and challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
756	Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R $\alpha$ complex. <i>Antibody Therapeutics</i> , 2023, 6, 38-48.	1.2	0
758	Spatial transcriptomics demonstrates the role of CD4 <sup>+</sup> T cells in effector CD8 <sup>+</sup> T cell differentiation during chronic viral infection. <i>Cell Reports</i> , 2022, 41, 111736.	2.9	7
759	Gastric Cancer and the Immune System: The Key to Improving Outcomes?. <i>Cancers</i> , 2022, 14, 5940.	1.7	5
760	Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. <i>Journal of Hepatology</i> , 2023, 78, 376-389.	1.8	13
761	KrÄppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells. <i>Science Advances</i> , 2022, 8, .	4.7	7
762	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. <i>Immuno</i> , 2022, 2, 671-691.	0.6	2
764	Identification of human progenitors of exhausted CD8 <sup>+</sup> T cells associated with elevated IFN- $\gamma$ response in early phase of viral infection. <i>Nature Communications</i> , 2022, 13, .	5.8	8
765	IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8 <sup>+</sup> T cells to overcome immunotherapy resistance in cancer. <i>Nature Cell Biology</i> , 2022, 24, 1754-1765.	4.6	22
766	Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in WaldenstrÄm macroglobulinemia. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	6
767	Interleukin-10 induces expression of CD39 on CD8 <sup>+</sup> T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. , 2022, 10, e005436.		3
768	CD8 <sup>+</sup> T cell exhaustion and cancer immunotherapy. <i>Cancer Letters</i> , 2023, 559, 216043.	3.2	18
769	IL-2 engineered MSCs rescue T cells in tumours. <i>Nature Cell Biology</i> , 2022, 24, 1689-1691.	4.6	2

#	ARTICLE	IF	CITATIONS
770	Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. <i>Nature Immunology</i> , 2023, 24, 267-279.	7.0	61
771	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. <i>JACC: CardioOncology</i> , 2022, 4, 635-645.	1.7	4
772	What do cancer-specific T cells "see"? , 2023, 2, .		1
773	Lymphoid tissue residency: A key to understand Tcf-1+PD-1+ T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
774	NK cells reduce anergic T cell development in early-stage tumors by promoting myeloid cell maturation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
775	Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors. , 2022, 10, e005293.		11
776	Identification of hub genes correlated with tumor-associated M1-like macrophage infiltration in soft tissue sarcomas. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
778	The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. <i>Immunity</i> , 2023, 56, 93-106.e6.	6.6	24
779	Age-associated remodeling of T cell immunity and metabolism. <i>Cell Metabolism</i> , 2023, 35, 36-55.	7.2	19
780	Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. <i>Cancer Cell</i> , 2022, 40, 1600-1618.e10.	7.7	40
781	LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. <i>Cancer Immunology Research</i> , 2023, 11, 171-183.	1.6	6
782	Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. <i>Cancer Immunology Research</i> , 2023, 11, 164-170.	1.6	5
783	Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect. <i>Clinical Cancer Research</i> , 2023, 29, 667-683.	3.2	12
784	Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
785	Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. <i>Immunity</i> , 2023, 56, 162-179.e6.	6.6	23
786	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
787	CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. <i>Immunity</i> , 2023, 56, 107-124.e5.	6.6	75
789	MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. <i>Cancer Cell</i> , 2023, 41, 235-251.e9.	7.7	22

#	ARTICLE	IF	CITATIONS
791	Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	15
792	Lenvatinib enhances antitumor immunity by promoting the infiltration of <sup>+</sup> TCF1 <sup>+</sup> CD8 <sup>+</sup> T cells in HCC via blocking VEGFR2. <i>Cancer Science</i> , 0, , .	1.7	3
793	Neoantigens: promising targets for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	112
794	Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. <i>Nature Cancer</i> , 0, , .	5.7	10
795	Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	39
796	Expression of glucose transporter-1 in follicular lymphoma affected tumor-infiltrating immunocytes and was related to progression of disease within 24 months. <i>Translational Oncology</i> , 2023, 28, 101614.	1.7	1
797	Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 28, 99-115.	1.8	1
798	Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. <i>Journal of Immunology</i> , 2022, 209, 660-664.	0.4	5
799	Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. <i>Nature Cancer</i> , 0, , .	5.7	14
800	Biomarkers of tumor-reactive CD4 <sup>+</sup> and CD8 <sup>+</sup> TILs associate with improved prognosis in endometrial cancer.. , 2022, 10, e005443.		12
801	IFN $\gamma$ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <i>Nature Communications</i> , 2023, 14, .	5.8	12
804	STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	12
805	CD200 <sup>+</sup> cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
807	BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells. <i>Leukemia</i> , 2023, 37, 580-592.	3.3	6
808	Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	0
810	Immune checkpoint receptors in autoimmunity. <i>Current Opinion in Immunology</i> , 2023, 80, 102283.	2.4	16
811	Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. , 2023, 11, e005509.		7
812	Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation. <i>Cell Reports</i> , 2023, 42, 112250.	2.9	2



#	ARTICLE	IF	CITATIONS
813	Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
814	Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses. <i>Journal of Immunology</i> , 2023, 210, 869-879.	0.4	2
815	Second near-infrared light-activated semiconducting polymer nanomediators enable three-in-one tumor microenvironment modulation for combination immunotherapy. <i>Nano Today</i> , 2023, 50, 101833.	6.2	9
816	The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114646.	2.5	7
817	The elevated expression of LAG-3 on CD8+T cells correlates with disease severity of pulmonary TB. <i>Microbial Pathogenesis</i> , 2023, 179, 106089.	1.3	3
818	Systems biology approaches to unravel lymphocyte subsets and function. <i>Current Opinion in Immunology</i> , 2023, 82, 102323.	2.4	0
819	Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
820	Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis. <i>Hepatology Communications</i> , 2023, 7, .	2.0	1
821	Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetineâ€Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles. <i>Advanced Science</i> , 2023, 10, .	5.6	9
823	Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	18
824	Steroid hormone regulation of immune responses in cancer. <i>Immunometabolism</i> , 2022, 4, e00012.	0.7	3
825	Immunotoxin-Î±CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	3
826	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
827	Combination IFNÎ² and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. <i>Cancer Immunology Research</i> , 2023, 11, 466-485.	1.6	1
828	IL-1 receptorâ€associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	5
829	Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2023, 11, 570-582.	1.6	2
831	Learning from the nexus of autoimmunity and cancer. <i>Immunity</i> , 2023, 56, 256-271.	6.6	4
832	XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections. <i>Cell Reports</i> , 2023, 42, 112123.	2.9	1

#	ARTICLE	IF	CITATIONS
833	T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
834	The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. <i>Immunity</i> , 2023, 56, 813-828.e10.	6.6	12
835	Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma. <i>ELife</i> , 0, 12, .	2.8	6
836	Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. <i>Hepatology</i> , 2023, 78, 1402-1417.	3.6	4
837	Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. <i>Cancer Cell</i> , 2023, 41, 585-601.e8.	7.7	19
838	High endothelial venules in cancer: Regulation, function, and therapeutic implication. <i>Cancer Cell</i> , 2023, 41, 527-545.	7.7	5
839	Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. , 2023, , .		1
840	Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates CAR T cell solid tumor efficacy. <i>Human Gene Therapy</i> , 0, , .	1.4	0
841	Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	8
842	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
843	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4786.	1.8	0
844	De-novo reconstruction and identification of transcriptional gene regulatory network modules differentiating single-cell clusters. <i>NAR Genomics and Bioinformatics</i> , 2023, 5, .	1.5	0
845	Exhausted CD8+ T cells face a developmental fork in the road. <i>Trends in Immunology</i> , 2023, 44, 276-286.	2.9	5
846	Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	2
847	IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. <i>Cancer Research Communications</i> , 2023, 3, 576-591.	0.7	6
848	Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. <i>Cell</i> , 2023, 186, 1127-1143.e18.	13.5	71
849	Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. <i>Molecular Cell</i> , 2023, 83, 1216-1236.e12.	4.5	13
851	T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma. , 2023, 2, .		0

#	ARTICLE	IF	CITATIONS
852	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. <i>Liver Cancer International</i> , 2023, 4, 58-72.	0.2	0
853	CD83 expression characterizes precursor exhausted T cell population. <i>Communications Biology</i> , 2023, 6, .	2.0	2
854	Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells. <i>Cancer Research</i> , 2023, 83, 1815-1833.	0.4	7
855	Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. <i>Nature Communications</i> , 2023, 14, .	5.8	9
856	Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	10
857	Clonal Spreading of Tumor-Infiltrating T Cells Underlies the Robust Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2023, 11, 847-862.	1.6	1
858	Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. <i>Cancer Cell</i> , 2023, 41, 776-790.e7.	7.7	16
859	A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade. <i>Cancer Cell</i> , 2023, 41, 653-655.	7.7	1
860	Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4275-4293.	2.9	7
861	T <sub>STEM</sub> -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	20
863	Dietary tryptophan metabolite released by intratumoral <i>Lactobacillus reuteri</i> facilitates immune checkpoint inhibitor treatment. <i>Cell</i> , 2023, 186, 1846-1862.e26.	13.5	92
864	DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells. <i>Immunity</i> , 2023, 56, 959-978.e10.	6.6	5
865	Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. <i>Nature Biomedical Engineering</i> , 2023, 7, 1188-1203.	11.6	9
866	T cell heterogeneity, progenitor-progeny relationships, and function during latent and chronic viral infections. <i>Immunological Reviews</i> , 2023, 316, 136-159.	2.8	3
867	Cuproptosis-related molecular subtypes direct T cell exhaustion phenotypes and therapeutic strategies for patients with lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
868	Cell-Intrinsic CD38 Expression Sustains Exhausted CD8 <sup>+</sup> T Cells by Regulating Their Survival and Metabolism during Chronic Viral Infection. <i>Journal of Virology</i> , 2023, 97, .	1.5	6
869	Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice. <i>Nature Communications</i> , 2023, 14, .	5.8	3
870	Dynamics and specificities of T cells in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2023, 23, 295-316.	12.8	49

#	ARTICLE	IF	CITATIONS
871	Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. <i>Cancer Cell</i> , 2023, 41, 871-886.e10.	7.7	18
872	Expression and function of CD51 on CD8 T cells as an immunomodulatory target. <i>Biochemical and Biophysical Research Communications</i> , 2023, 661, 56-63.	1.0	0
873	The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	0
874	The metabolic cross-talk between cancer and T cells. <i>Trends in Biochemical Sciences</i> , 2023, 48, 597-609.	3.7	1
877	Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. <i>Nature Immunology</i> , 2023, 24, 869-883.	7.0	14
878	Late-stage MC38 tumours recapitulate features of human colorectal cancer â€“ implications for appropriate timepoint selection in preclinical studies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
900	Localization, tissue biology and T cell state â€” implications for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2023, 23, 807-823.	10.6	10
960	Regulation of CD8+ T memory and exhaustion by the mTOR signals. , 2023, 20, 1023-1039.		4
988	Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. , 2023, 40, .		3
994	Stem-like exhausted and memory CD8+ T cells in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 780-798.	12.8	5
1025	Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1039	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. <i>Experimental and Molecular Medicine</i> , 2023, 55, 2287-2299.	3.2	7
1053	Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 18253-18270.	1.2	0
1055	How chemokines organize the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2024, 24, 28-50.	12.8	0